Clinical Study Data Presentation, Product Launches, Technology Deployments, and Stock Price Movements - Research Report on Celgene, Mylan, Valeant, Health Management, and CareFusion Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, December 17, 2013 NEW YORK, December 17, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Celgene Corporation (NASDAQ: CELG), Mylan Inc. (NASDAQ: MYL), Valeant Pharmaceuticals International Inc. (NYSE: VRX), Health Management Associates Inc. (NYSE: HMA), and CareFusion Corporation (NYSE: CFN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Celgene Corporation Research Report On December 10, 2013, Celgene Corporation's (Celgene) wholly owned subsidiary, Celgene International Sàrl, announced that it has presented updated analyses from MM-003, at the American Society of Hematology Annual Meeting in New Orleans, Louisiana. According to the Company, the MM-003 is a phase III study of pomalidomide plus low-dose dexamethasone, compared with high-dose dexamethasone in patients with refractory multiple myeloma who have failed therapy with both bortezomib and lenalidomide, administered either alone or in combination. According to Celgene, it previously reported that with a median follow-up of 10 months, pomalidomide plus low-dose dexamethasone significantly extended progression-free survival (PFS) (4.0 months vs. 1.9 months, HR=-0.48, p<0.001) and overall survival (OS) (12.7 months vs. 8.1 months, HR= 0.74, p<0.028) compared with high-dose dexamethasone. Celgene informed that the OS benefit was observed despite 50% of the patients in the high-dose dexamethasone arm receiving subsequent pomalidomide. Further, Celgene informed that in a retrospective analysis, the increase in ORR and median PFS were maintained for pomalidomide plus low-dose dexamethasone compared with high-dose dexamethasone regardless of modified high-risk cytogenetics (del (17p) or t(4;14)) (ORR: 25% vs. 9%, P=0.071; PFS: 3.8 vs. 1.1 months, HR=0.44, P<0.001) or standard-risk cytogenetics (ORR: 35% vs. 10%, P<0.001; PFS: 4.2 vs. 2.3 months, HR=0.55, P<0.001). The Full Research Report on Celgene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/7f47_CELG -- Mylan Inc. Research Report On December 5, 2013, Mylan Inc. (Mylan) announced that the Company's U.S. based subsidiary, Mylan Pharmaceuticals Inc., launched Cabergoline Tablets USP, 0.5 mg, which are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. Mylan informed that it has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for 0.5mg Cabergoline Tablets USP. The Full Research Report on Mylan Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/5a20_MYL -- Valeant Pharmaceuticals International Inc. Research Report On December 12, 2013, Valeant Pharmaceuticals International Inc.'s (Valeant) stock declined 0.23%, ending the day's session at $106.24. Over the previous three trading sessions, shares of Valeant declined 1.60%, compared to the S&P 500 which declined 1.82% during the same period. The Full Research Report on Valeant Pharmaceuticals International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/9fdd_VRX -- Health Management Associates Inc. Research Report On December 12, 2013, Health Management Associates Inc.'s (Health Management) stock rose 0.23%, ending the day's session at $13.00. Over the previous three trading sessions, shares of Health Management declined 0.61%, compared to the S&P 500 which declined 1.82% during the same period. The Full Research Report on Health Management Associates Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/9ce8_HMA -- CareFusion Corporation Research Report On December 11, 2013, CareFusion Corporation (CareFusion) reported that Olathe Health System has rolled out new technology, designed to help improve medication safety at the Olathe Medical Center and Miami County Medical Center. The Company informed that the new technology from CareFusion and Cerner is designed to help hospitals reduce medication administration errors by enabling nurses to pre-program intravenous (IV) medication orders from the hospitals' Cerner Millennium electronic health record (EHR) system to the CareFusion Alaris System smart infusion pump through barcode scanning at the patient bedside. The Company added that the CareFusion Alaris System and the Cerner CareAware iBus can reduce the number of manual steps required to program an infusion order from as many as 22 key presses down to two or three confirmation steps. The Full Research Report on CareFusion Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/4933_CFN ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Clinical Study Data Presentation, Product Launches, Technology Deployments, and Stock Price Movements - Research Report on
Press spacebar to pause and continue. Press esc to stop.